Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Mike Czapar, ...

Eli Lilly's Q4 FY24 guidance adjustment is due to supply chain factors, not demand, creating an attractive buying opportunity with a 'Buy' rating. Despite a modest 0.6% revenue reduction, LLY ...

Eli Lilly and Company (NYSE:LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription,... ByInvesting ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.

Eli Lilly is just weeks away from launching ... but has initially been made available in vials only as Lilly waits for EU approval of the KwikPen format later this year. Northern Ireland still ...

Zepbound (tirzepatide) is only available on ... found both methods of drug administration easy to manage. Eli Lilly also states that vial forms are cheaper than the auto-injector pre-filled ...

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound ... to offer the lower-cost version of Zepbound (tirzepatide) made available in August.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

Patients who bought stockpiles of alternative GLP-1 drugs online aren't sure what to do with them after learning that the compounding pharmacy that made them didn't have the right license.